Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1998-08-07
2000-10-03
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
562560, C07L25114, A61K 31197
Patent
active
061274208
ABSTRACT:
Selective and irreversible inhibitors of neuronal isoform of nitric oxide synthase catalyzed production of nitric oxide are L-ornithine or L-lysine derivatives having the formula ##STR1## wherein Q is H or (CH.sub.2).sub.r CH.sub.3 where r ranges from 0 to 15, x is 1 or 2, R" is CH.sub.2 or C(H) (CH.sub.2).sub.y CH.sub.3 where y ranges from 0 to 5, R' is CH.sub.2 or C(H) (CH.sub.2).sub.z CH.sub.3 where z ranges from 0 to 5, R is H or (CH.sub.2).sub.s CH.sub.3 where s ranges from 0 to 5, with none or only one of R, R' and R" providing an alkyl substituent on ornithine or lysine moiety, R.sup.III is OH or is an alkoxy group of 1 to 6 carbon atoms or is an amino acid or peptide attached in amide linkage through its free .alpha.-amino group, and R.sup.IV is --H or an acyl group of 1 to 6 carbon atoms or is an amino acid or peptide attached in amide linkage through its free .alpha.-carboxylate group, and mixtures thereof with corresponding D-isomers. A preferred compound is N.sup.5 -(1-imino-3-butenyl)-L-ornithine. The compounds are useful for treatment of migraine headaches, stroke, pain due to stimulation of nNOS-containing neurons including chronic visceral pain, drug addiction, Parkinson's disease, schizophrenia, and epilepsy.
REFERENCES:
patent: 5281627 (1994-01-01), Griffith
Babu, R. B., et al, J. Biol. Chem., 273, No. 15 8882-8889 (Apr. 10, 1998).
Silverman R. B., J. Med. Chem. 40, 2813-2817 (1997).
Medline Abstract of Samii, S. A., et al, Am. J. Physiol., 267, E124-E134 (1994); Identifier 94324471.
Medline Abstract of Bickel, U., et al, J. Pharm. Expt. Therap. 268(2), 791-796 (1994); Identifier 94157782.
Medline Abstract of Toth, I., J. Drug Targeting 2, 217-239 (1994); Identifier 95111928.
Medline Abstract of Tamai, I., et al, J. Pharmacol. Expt. Therap. 280, 410-415 (1997); Identifier 97149414.
Abstract of Pietrowski, R., et al. Biol. Psych. 39, 332-340 (1996); PMID:8704064; UI:96252654.
Scannell, J. P., et al, The Journal of Antibiotics, vol. XXV, No. 3, 179-184 (Mar. 1972).
Palacios, M., et al, Biochem. Biophys. Res. Commun., 165, No. 2, 802-809 (Dec. 1989).
Rees, D. D., et al, Br. J. Pharmacol., 101, 746-752 (1990).
McCall, T. B., et al, Br. J. Pharmacol., 102, 234-238 (1991).
Moore, W. M., et al, J. Med. Chem., 37, 3886-3888 (1994).
Boga Ramesh Babu
Griffith Owen W.
Gerstl Robert
The Medical College of Wisconsin Research Foundation Inc.
LandOfFree
L-N.sup.5 -(1-imino-3-alkenyl) ornithine and related compounds a does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with L-N.sup.5 -(1-imino-3-alkenyl) ornithine and related compounds a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and L-N.sup.5 -(1-imino-3-alkenyl) ornithine and related compounds a will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-196390